| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 01/03/2003 | WO2002002603A3 Protein modification and maintenance molecules |
| 01/03/2003 | WO2002000727A3 Gp286 nucleic acids and polypeptides |
| 01/03/2003 | WO2001098468A3 Proteases |
| 01/03/2003 | WO2001098357A3 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| 01/03/2003 | WO2001089502A3 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
| 01/03/2003 | WO2001081581A9 Compositions and methods for the therapy and diagnosis of acne vulgaris |
| 01/03/2003 | WO2001081551A8 Retinal pigment epithelial cell lines with extended life-span and their applications |
| 01/03/2003 | WO2001044260A8 Novel purines |
| 01/03/2003 | CA2714072A1 Nasal devices comprising a mouthpiece unit through which a subject exhales and a nosepiece including an inflatable cuff member |
| 01/03/2003 | CA2451885A1 Method and material for treating immune diseases |
| 01/03/2003 | CA2451686A1 A novel g protein-coupled receptor, gave 3 |
| 01/03/2003 | CA2451625A1 Substituted n-acyl-aniline derivatives, the preparation thereof and the use thereof as pharmaceutical compositions |
| 01/03/2003 | CA2451602A1 Combination therapy of an sodm and a corticosteroid for prevention and/or treatment of inflammatory disease |
| 01/03/2003 | CA2451250A1 Modulating serum amyloid a interaction with tanis and agents useful for same |
| 01/03/2003 | CA2451185A1 Spherical protein particles and methods of making and using them |
| 01/03/2003 | CA2450969A1 Nucleic acid-associated proteins |
| 01/03/2003 | CA2450954A1 Method of treating atherosclerosis and other inflammatory diseases |
| 01/03/2003 | CA2450925A1 G-protein coupled receptors |
| 01/03/2003 | CA2450921A1 Protein modification and maintenance molecules |
| 01/03/2003 | CA2450583A1 Antihistamines for the treatment of nasal congestion and nasal obstruction |
| 01/03/2003 | CA2450579A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2450562A1 Tyrosine kinase inhibitors |
| 01/03/2003 | CA2450555A1 (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| 01/03/2003 | CA2450492A1 Nasal devices comprising a mouthpiece unit through which a subject exhales and a nosepiece including an inflatable cuff member |
| 01/03/2003 | CA2450478A1 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/03/2003 | CA2450475A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2450002A1 Benzenesulfonyl(thio)ureas for the treatment of septic shock and sirs |
| 01/03/2003 | CA2449441A1 3-fluoro-pyrrolidines as antidiabetic agents |
| 01/02/2003 | US20030004351 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
| 01/02/2003 | US20030004324 31 human secreted proteins |
| 01/02/2003 | US20030004317 Nucleic acids encoding anti-human alphanubeta3 and alphanubeta5 antibodies |
| 01/02/2003 | US20030004212 Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists |
| 01/02/2003 | US20030004200 Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-YL] benzenesulfonamide |
| 01/02/2003 | US20030004196 Antiinflamamtory agents; autoimmune disease |
| 01/02/2003 | US20030004194 Method for treating fibrotic diseases or other indications VI |
| 01/02/2003 | US20030004193 Immunomodulators; antiinflammatory agents |
| 01/02/2003 | US20030004186 Anticoagulants; cardiovascular disorders; central nervous system disorders |
| 01/02/2003 | US20030004176 Mixture of analgesic and addition reducting compound of a gamma-aminobutyric acid |
| 01/02/2003 | US20030004174 Antiinflammatory agents, anticancer agents, antihistamines, central nervous system disorders |
| 01/02/2003 | US20030004172 Cardiovascular disorders, osteoporosis, multiple sclerosis, antiarthritic agents |
| 01/02/2003 | US20030004165 Polyazanaphthalene compounds and pharmaceutical use thereof |
| 01/02/2003 | US20030004164 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004161 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004153 Novel heteroaryl-diazabicycloalkanes |
| 01/02/2003 | US20030004151 Cyclic derivatives as modulators of chemokine receptor activity |
| 01/02/2003 | US20030004143 In situ supplying; anticancer, antitumor agents |
| 01/02/2003 | US20030004137 Muscle relaxants, controlling immunology, strokes, antidiabetic agents |
| 01/02/2003 | US20030004136 IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases |
| 01/02/2003 | US20030004132 Binding to galectins; therapy for autoimmune disease |
| 01/02/2003 | US20030004129 Formulations of adenosine a1 agonists |
| 01/02/2003 | US20030004127 Formulations of adenosine a1 agonists |
| 01/02/2003 | US20030004126 Formulations of adenosine A1 agonists |
| 01/02/2003 | US20030004117 Methods for inhibiting angiogenesis |
| 01/02/2003 | US20030004106 Interleukin-1 receptor antagonist-related molecules and uses thereof |
| 01/02/2003 | US20030003576 Peripheral blood fibrocytes differentiation pathway and migration to wound sites |
| 01/02/2003 | US20030003532 Novel nucleic acid sequences encoding human slit-, megf-, and roundabout-like polypeptides |
| 01/02/2003 | US20030003516 Therapeutic and diagnostic uses of antibody specificity profiles |
| 01/02/2003 | US20030003462 Novel human interleukin-like proteins and polynucleotides encoding them |
| 01/02/2003 | US20030003169 Prepared by fermenting an aqueous Glycine max (L.) extract with at least one lactic acid bacteria together with at least one yeast |
| 01/02/2003 | US20030003163 For restoration and maintenance of gingival and periodontal health; antiplaque/antitar agents; mouthwash |
| 01/02/2003 | US20030003121 Antiallergic agent |
| 01/02/2003 | US20030000518 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| 01/02/2003 | EP1270599A1 Salmon-origin chondroitin sulfate |
| 01/02/2003 | EP1270577A1 Furoisoquinoline derivatives, process for producing the same and use thereof |
| 01/02/2003 | EP1270573A1 Xanthine and phenazone acesulfam-H complexes with improved taste, process for their preparation and their use |
| 01/02/2003 | EP1270572A1 Condensed pyrazole derivatives, process for producing the same and use thereof |
| 01/02/2003 | EP1270570A1 Amide compounds and use thereof |
| 01/02/2003 | EP1270569A1 Substituted tryptophan derivatives |
| 01/02/2003 | EP1270559A1 Novel imidazole derivatives with anti-inflammatory activity |
| 01/02/2003 | EP1270551A1 Urea derivatives with antiproteolytic activity |
| 01/02/2003 | EP1269999A1 Ultraviolet-shielding adhesive preparation |
| 01/02/2003 | EP1269196A1 Method of screening for inhibitors of osteopontin |
| 01/02/2003 | EP1269183A1 Assay for agents that induce chemokinesis |
| 01/02/2003 | EP1268861A2 Diagnosis of diseases associated with dna transcription |
| 01/02/2003 | EP1268857A2 Diagnosis of diseases associated with gene regulation |
| 01/02/2003 | EP1268802A2 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 01/02/2003 | EP1268792A2 Wnt-7b-like polypeptides and nucleic acids encoding same |
| 01/02/2003 | EP1268787A2 Human tap-like protein (transporter associated in antigen processing/presentation) |
| 01/02/2003 | EP1268784A2 Genes involved in intestinal inflammatory diseases and use thereof |
| 01/02/2003 | EP1268783A2 Anti-angiogenic and anti-tumor properties of matin and other laminin domains |
| 01/02/2003 | EP1268781A2 G12l, a gene associated with the thermal response |
| 01/02/2003 | EP1268773A1 Immune system-related polynucleotides, polypeptides, and antibodies |
| 01/02/2003 | EP1268760A1 Recombinant proteins containing shiga-like toxin and vascular endothelial growth factor fragments |
| 01/02/2003 | EP1268554A2 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| 01/02/2003 | EP1268553A1 Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract |
| 01/02/2003 | EP1268549A2 Method of identifying inhibitors of tie-2 |
| 01/02/2003 | EP1268543A2 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| 01/02/2003 | EP1268540A2 Proteins amf-1 to amf-10 and nucleic acids encoding same |
| 01/02/2003 | EP1268495A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 01/02/2003 | EP1268494A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 01/02/2003 | EP1268487A1 Tricyclic protein kinase inhibitors |
| 01/02/2003 | EP1268484A1 Condensed imidazoles as histamine h3 receptor ligands |
| 01/02/2003 | EP1268483A1 Condensed imidazoles as histamine h3 receptor ligands |
| 01/02/2003 | EP1268481A2 Kinase inhibitors as therapeutic agents |
| 01/02/2003 | EP1268477A1 Substituted beta-carbolines with ikb-kinase inhibiting activity |
| 01/02/2003 | EP1268472A1 3-aminopyrazole inhibitors of cyclin dependent kinases |
| 01/02/2003 | EP1268471A1 N-heterocyclic derivatives as nos inhibitors |
| 01/02/2003 | EP1268455A2 Piperazine derivatives |
| 01/02/2003 | EP1268453A1 Estrogen agonist/antagonist metabolites |
| 01/02/2003 | EP1268445A1 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases |